WHIPPANY, N.J., July 28, 2016 /PRNewswire/ -- Bayer reinforced its commitment to science and to the hemophilia community by awarding six grants to clinicians and researchers from hospitals and research institutions across the United States (U.S.) as part of the Bayer Hemophilia Awards Program (BHAP).
The largest program of its kind, BHAP exemplifies Bayer's commitment to support research and educational initiatives in hemophilia and related bleeding disorders and its overarching mission of "Science for a Better Life." This year, 16 recipients in 11 countries received grants worth nearly $2 million. Since its founding in 2002, BHAP has awarded more than 255 grants totaling in excess of $31 million to researchers and caregivers from 32 countries around the world.
"For more than 20 years Bayer has been committed to working with the hemophilia community, and the BHAP grants have played a significant role in driving the next generation of insights for patients and their families," said Dario Mirski, MD, Senior Vice President & Head Medical Affairs Americas, Bayer. "It is with great pride that we continue to support research and clinical efforts that have the potential to make an impact on the diagnosis and treatment of bleeding disorders."
The U.S. BHAP winners, which were announced last night during a reception at the World Federation of Hemophilia 2016 World Congress in Orlando, Fla., are:
- Dr. Moanaro Biswas, University of Florida Cancer & Genetics Research Center
- Dr. James Dahlman, Georgia Institute of Technology
- Dr. Gary Gilbert, Boston VA Research Institute
- Dr. Rahul Khanna, University of Mississippi
- Dr. Michael Milone, University of Pennsylvania
- Dr. Maurizio Tomaiuolo, University of Pennsylvania
"Gene therapy is such an exciting new area in medicine that holds promise for many disease areas, including hemophilia, and I'm honored to be selected as a 2016 BHAP winner," said Dr. James Dahlman of the Georgia Institute of Technology in Atlanta, Ga. "With Bayer's generous support, I can continue this important research."
BHAP awardees are selected by a global panel of distinguished hemophilia clinicians, researchers and caregivers. BHAP support has contributed to more than 500 publications, poster presentations and other scientific communications by awardees.
This year, BHAP awards were presented in the following categories: Special Projects – which provides support for a wide range of scientific research; Early Career Investigator – which provides salary support and research funds for junior faculty members to undertake mentored and/or basic research projects; Fellowship Project – which facilitates the development of specific clinical expertise for applicants who have completed medical training; Caregiver – which recognizes the essential role of caregivers and allied health professionals; and Outcomes Research – which encourages the development of relevant tools for outcome assessment, or their validation and applications in different health care situations.
To learn more about BHAP, please visit the website here.
About Bayer Hematology
Hematology at Bayer includes numerous compounds in various stages of development for hemophilia, sickle cell anemia, and other blood and bleeding disorders. Together, these compounds reflect the company's commitment to research and development, prioritizing specific targets for intervention with the potential to improve the way that rare blood and bleeding disorders are treated.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their lives. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.
Bayer® and the Bayer Cross® are registered trademarks of Bayer.
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Intended for U.S. media only
SOURCE Bayer Corporation